S. LOUISE PHANSTIEL - Corporate Board Profile

MYRIAD GENETICS INC

Filing Date	Source Excerpt
2013-10-15	S. Louise Phanstiel (1) (3) 55 Director ... Member of the Audit Committee. ... Member of the Nominating and Governance Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2013 to each of our non-employee directors who served during fiscal 2013. ... S. Louise Phanstiel Fees Earned or Paid in Cash ($) 98,500 Option Awards ($) 304,854 Total ($) 403,354
2014-10-14	S. Louise Phanstiel (1) (3) 56 Director ... (1) Member of the Audit Committee. (3) Member of the Nominating and Governance Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2014 to each of our non-employee directors who served during fiscal 2014. S. Louise Phanstiel Fees Earned or Paid in Cash ($) 94,500 Option Awards ($) 290,517 Total ($) 385,017
2015-10-15	S. Louise Phanstiel (1) (3) 57 Director ... (1) Member of the Audit Committee. (3) Member of the Nominating and Governance Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2015 to each of our nonemployee directors who served during fiscal 2015. ... S. Louise Phanstiel 95,500 346,800 442,300
2016-10-11	S. Louise Phanstiel (1)(3) 58 Director ... (1) Member of the Audit Committee. (3) Member of the Nominating and Governance Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2016 to each of our nonemployee directors who served during fiscal 2016. S. Louise Phanstiel 97,500 Fees Earned or Paid in Cash ($) 318,525 Restricted Stock Unit Awards ($) 416,025 Total ($)
2017-10-12	S. Louise Phanstiel, a director of Myriad since September 2009, ... Member of the Audit Committee. ... Member of the Nominating and Governance Committee. ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2017 to each of our nonemployee directors who served during fiscal year 2017. ... S. Louise Phanstiel ... 97,500 Fees Earned or Paid in Cash, 250,000 Restricted Stock Unit Awards, 347,500 Total.
2018-10-10	S. Louise Phanstiel (1) (3) 60 Director ... Member of the Audit Committee. ... Member of the Nominating and Governance Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2018 to each of our nonemployee directors ... S. Louise Phanstiel 347,494
2019-10-16	S. Louise Phanstiel (1) (3) 61 Director ... Member of the Audit Committee. ... Member of the Nominating and Governance Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2019 to each of our nonemployee directors ... S. Louise Phanstiel 99,500 Fees Earned or Paid in Cash, 299,988 Restricted Stock Unit Awards, 399,488 Total.
2020-10-15	S. Louise Phanstiel, Chair of the Board of Directors, has been a Director of Myriad since September 2009... Ms. Phanstiel also provides the Board with financial accounting, internal control and public company reporting expertise... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2020 to each of our nonemployee directors... S. Louise Phanstiel 103,019 300,005 401,774
2021-04-15	S. Louise Phanstiel, Chair of the Board of Directors, has been a director of Myriad since September 2009... Age: 62... Committees: Audit and Finance Committee, Compensation and Human Capital Committee, Nominating and Governance Committee... Director Compensation Table: S. Louise Phanstiel Fees Earned or Paid in Cash: 124,750, Stock Awards: 299,984, Total: 424,734.
2022-04-14	S. Louise Phanstiel, Chair of the Board of Directors, has been a director of Myriad since September 2009, and held several executive positions at Anthem, Inc., formerly WellPoint, Inc. from 1996 to 2007. She was President, Specialty Products, which included behavioral health services; Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman; and Chief Accounting Officer, Controller and Chief Financial Officer for all WellPoint, Inc. subsidiaries. Previously, Ms. Phanstiel was a partner at the international services firm PricewaterhouseCoopers, LLP, formerly Coopers & Lybrand, LLP where she specialized in insurance. Ms. Phanstiel's life science experience includes having previously served on the Board of Directors and Chair of the Audit Committees at publicly traded companies, Inveresk Research Group, Inc. and Verastem, Inc. Ms. Phanstiel is currently a member of the Board of Directors of Butterfly Network, Inc. The Board of Directors has determined that Ms. Phanstiel should serve on the Board for the following reasons: She provides the Board with important expertise in the healthcare industry based on her extensive experience in several senior positions at WellPoint, Inc. This expertise is critical as we rely on healthcare third-party reimbursement for our molecular diagnostic testing services. Ms. Phanstiel also provides the Board with financial accounting, internal control and public company reporting expertise from her work at Coopers & Lybrand, LLP and as a Certified Public Accountant. In addition, she provides the Board with business, financial and investment expertise, as well as management expertise, resulting from managing and service as a director of publicly traded companies. Age: 63 Director Since:2009 Committees: Audit and Finance Committee, Compensation and Human Capital Committee, Nominating, Environmental, Social and Governance Committee
2023-04-12	S. Louise Phanstiel, Chair of the Board, has been a director of Myriad since September 2009, and held several executive positions at Anthem, Inc., formerly WellPoint, Inc. from 1996 to 2007. She was President, Specialty Products, which included behavioral health services; Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman; and Chief Accounting Officer, Controller and Chief Financial Officer for all WellPoint, Inc. subsidiaries. Previously, Ms. Phanstiel was a partner at the international services firm PricewaterhouseCoopers, LLP, formerly Coopers & Lybrand, LLP where she specialized in insurance. Ms. Phanstiel's life science experience includes having previously served on the board of directors and Chair of the audit committees at publicly traded companies, Inveresk Research Group, Inc. and Verastem, Inc. Ms. Phanstiel is currently a member of the board of directors of Butterfly Network, Inc. The Board has determined that Ms. Phanstiel should serve on the Board for the following reasons: She provides the Board with important expertise in the healthcare industry based on her extensive experience in several senior positions at WellPoint, Inc. This expertise is critical as we rely on healthcare third-party reimbursement for our molecular diagnostic testing services. Ms. Phanstiel also provides the Board with financial accounting, internal control and public company reporting expertise from her work at Coopers & Lybrand, LLP and as a Certified Public Accountant. In addition, she provides the Board with business, financial and investment expertise, as well as management expertise, resulting from managing and service as a director of publicly traded companies.
2024-04-17	S. Louise Phanstiel, Chair of the Board, has been a director of Myriad since September 2009 and assumed the Chair of the Board role in March 2020... Ms. Phanstiel is currently a member of the board of directors of Butterfly Network, Inc.... The following table shows the total compensation paid or accrued during the year ended December 31, 2023 to each of our non-employee directors who served during fiscal year 2023... S. Louise Phanstiel $213,500 cash fees and $349,988 stock awards totaling $563,488.